Breaking News

Flow Eighteen38 Expands Production and Biophysical Capabilities

Investment of $5.5mn supports expansion of services to include pre-CMC stages for faster and successful biotherapeutics development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Flow Eighteen38, a protein sciences division of FairJourney Biologics S.A. (FJB), is receiving a $5.58 million investment from its parent to bolster protein production and biophysical characterization capabilities. FJB is a provider of discovery services and focused on the optimization of antibodies. The investment will be used to develop a dedicated, fit-for-purpose laboratory, designed to host a range of new and bespoke, state-of-the-art equipment to double protein purification capacity. Th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters